drugset / Trial / NCT01796327

A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy Volunteers

NCT01796327

Phase 1 Completed 14 enrolled Pfizer
CrossoverOpen-labelBasic science

Summary

This study aims to determine the proportion of study drug dacomitinib or PF-00299804, that is taken up from the digestive tract into the body when given as an oral tablet compared with that taken up by an intravenous dose.

Timeline

Start
2013-04
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject DACOMITINIB ANHYDROUS Small molecule 20 mg Oral
Subject DACOMITINIB ANHYDROUS Small molecule 45 mg Oral

Indications

No indication recorded.